Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of leuprorelin injectable emulsion in premenopausal breast cancer
CTR20240920Phase 3Completed
- Sponsor
- YD Bio
- Start
- Mar 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in breast cancer, sponsored by YD Bio. Primary endpoint: Proportion of patients with serum estradiol (E2) maintained at postmenopausal level (≤ 30 pg/mL). Started Mar 2024; status: completed.
02
Drugs
leuprolide
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20240920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240920.